Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cilastatin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tigecycline | DRUG | - |
| Imipenem | DRUG | - |
| Cilastatin | DRUG | - |
Inclusion Criteria: * Male or female subjects over 18 years of age. Bulgaria Only: Male or female subjects over 18 years of age and under 70 years of age. * Subjects known or suspected to have acute hospital-acquired pneumonia. Exclusion Criteria: * Presence of any of the following pulmonary cond...
Cilastatin is a small molecule being studied for the treatment of Bacterial Pneumonia. It is part of a combination therapy with imipenem, evaluated in a Phase 3 clinical trial for hospital-acquired pneumonia. The drug is investigational and not yet approved for this indication.
Cilastatin does not have a specific molecular target; it is a renal dehydropeptidase inhibitor that prevents the metabolism of imipenem in the kidneys, thereby increasing its concentration and effectiveness. It is used in combination with imipenem to treat bacterial infections.
Cilastatin is developed by Pfizer, Inc., a company publicly traded under the ticker symbol PFE. Pfizer is conducting clinical research on this drug for the treatment of Bacterial Pneumonia.
Cilastatin is in Phase 3 clinical development. A Phase 3 trial, NCT00080496, has been completed, evaluating the drug in combination with imipenem for hospital-acquired pneumonia. It remains investigational and has not received FDA approval.
Cilastatin has one completed Phase 3 clinical trial, NCT00080496, titled 'Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia.' This randomized, double-blind trial enrolled 430 participants in the United States and was not controlled.
No, Cilastatin is not the same as Imipenem. Cilastatin is a separate drug that is combined with imipenem to prevent its breakdown in the kidneys. The combination is used to treat bacterial infections, including hospital-acquired pneumonia.